News | March 09, 2012

First U.S. PAD Patient Enrolled in Forward-Looking OCT Clinical Trial

March 9, 2012 — Avinger Inc. announced the enrollment of the first U.S. patient in the CONNECT II global clinical trial evaluating the safety and efficacy of Ocelot. The device is the first chronic total occlusion (CTO) crossing catheter using forward-looking optical coherence tomography (OCT) to treat patients with peripheral artery disease (PAD).

The first patient was enrolled by Ian Cawich, M.D., of Arkansas Heart Hospital. This announcement comes two weeks after Dr. Bernhard Reimers enrolled the first European patient in the CONNECT II trial at Ospedale di Mirano in Mirano, Italy.

Currently CE marked, Ocelot is designed for crossing completely blocked arteries, or chronic total occlusions (CTOs), in the legs while simultaneously using OCT to navigate inside the arteries.

“We hope that physicians using Ocelot can now help prevent even more leg amputations in people suffering from PAD,” said Avinger founder and CEO John B. Simpson, Ph.D., M.D.

The Ocelot catheter uses OCT technology as a navigation tool with the goal of traversing CTOs more safely and effectively as part of a procedure to restore blood flow back to normal in the legs. It allows physicians, in real time, to see what’s happening inside the arteries during the actual intervention, giving patients a better chance to receive the best treatment possible during a single hospital visit.

“We are participating in CONNECT II because our patient, if treated with other current options on the medical market, could face amputation and death,” said Cawich. “With Avinger’s Ocelot, we believe this patient can be saved right now from both.”

For more information: http://avinger.com

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Overlay Init